Recent Announcements

Updated Introductory Statement of When and In Whom to Initiate Therapy

The introductory statement of When and In Whom to Initiate Therapy has been revised to reiterate that treatment will benefit almost all patients in all stages of chronic infection and that urgent initiation of therapy is needed in patients with certain conditions.

New Section: Management of Acute HCV Infection

The newest section of the AASLD/IDSA/IAS–USA hepatitis C Guidance, Management of Acute HCV Infection, is now available. Click here to access this section.

Updated Information on Drug Interactions

Updated information on drug interactions between simeprevir and certain immunosuppressant drugs has been added based on the manufacturer's revised product prescribing information. For more information see Unique Patient Populations.

New Section: Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy

The newest section of the AASLD/IDSA/IAS-USA hepatitis C Guidance, Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy, is now available. Click here to access this section.

Updated Statement on Drug-drug Interactions

Simeprevir concentration is increased by approximately 6-fold when coadministered with cyclosporine (in combination with daclatasvir [an investigational drug] and RBV). Coadministration of simeprevir with cyclosporine is not recommended. For more information see Unique Patient Populations.

New Section: When and In Whom to Initiate HCV Therapy

We are pleased to introduce the newest section of the Guidance, When and in Whom to Initiate HCV Therapy. Successful hepatitis C treatment results in sustained virologic response (SVR), which is tantamount to virologic cure; virologic cure is expected to benefit chronically infected persons.

Official Press Release - When and In Whom to Initiate HCV Therapy

View Official Press Release: When and In Whom to Initiate HCV Therapy Now Available at www.HCVguidelines.org

How to cite the Guidance in papers

The website as a whole.
AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. $$$Insert date accessed here$$$.

A section or specific page on the website.
For example, if citing the HCV Testing and Linkage to Care section:
AASLD-IDSA. HCV testing and linkage to care. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report/hcv-testing-and-linkage-care. $$$Insert date accessed here$$$.

Updates, Clarifications, and Corrections

Notable changes are highlighted in yellow for approximately 1 month.

Retreatment Box (Summary). Recommendations for Patients in Whom Previous ~~PEG/RBV~~ Treatment Has Failed

New Panel Members

We are pleased to announce a new member to the HCV Guidance Panel: Hugo E. Vargas, MD, of the College of Medicine, Mayo Clinic.